Response prediction by MALDI-TOF-MS serum peptide profiling of combination treatment with sorafenib and erlotinib in patients with non-small cell lung cancer.
Maria Rovithi
No relevant relationships to disclose
Joline S. Lind
No relevant relationships to disclose
Thang V Pham
No relevant relationships to disclose
Jaco C Knol
No relevant relationships to disclose
Henk M.W. Verheul
No relevant relationships to disclose
Egbert F Smit
No relevant relationships to disclose
Connie R. Jimenez
No relevant relationships to disclose